US ‘Operation Warp Speed’ To Ready 300 Million Vaccine Doses by End Of 2020
By HospiMedica International staff writers Posted on 01 May 2020 |

Image: Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (Photo courtesy of NIAID).
The Trump administration is reportedly bringing biotech, pharma and federal agencies together in a project dubbed “Operation Warp Speed” that aims to cut the COVID-19 vaccine’s development time and deliver 100 million doses in the US by the end of the year.
The World Health Organization estimates more than 100 coronavirus vaccine candidates to be currently in development. Experts do not expect a vaccine to be ready for at least 12 to 18 months. Under project “Operation Warp Speed”, pharmaceutical companies, government agencies and the military will work together to cut that time by up to eight months. The administration will help biopharma companies coordinate their individual efforts by providing assistance through federal agencies and the US military. The project is similar to the Manhattan Project-style joint initiative which brought different sectors together to develop the nation’s atomic bomb.
The officials are looking at a master trial protocol that would allow researchers to simultaneously study different vaccines instead of studying each vaccine separately through independent studies by pharmaceutical companies. The administration plans to speed up distribution by scaling up manufacturing capabilities as the vaccines enter large human trials. The goal of project “Operation Warp Speed” is to have 300 million doses of vaccine available by January.
In a media interview, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and a key member of the White House Coronavirus Task Force, said that developing a vaccine to combat the coronavirus outbreak by January was “doable.” Dr. Fauci said that it was possible to ready hundreds of millions of doses of a coronavirus vaccine by January. However, meeting the January deadline will ultimately depend upon whether the results of trials prove that the vaccine works.
“We're going to start ramping up production with the companies involved and you do that at risk, in other words you don't wait until you get an answer before you start manufacturing, you at risk, proactively, start making it, assuming it's going to work,” said Dr. Fauci. “And if it does, then you can scale up and hopefully get to that timeline.”
The World Health Organization estimates more than 100 coronavirus vaccine candidates to be currently in development. Experts do not expect a vaccine to be ready for at least 12 to 18 months. Under project “Operation Warp Speed”, pharmaceutical companies, government agencies and the military will work together to cut that time by up to eight months. The administration will help biopharma companies coordinate their individual efforts by providing assistance through federal agencies and the US military. The project is similar to the Manhattan Project-style joint initiative which brought different sectors together to develop the nation’s atomic bomb.
The officials are looking at a master trial protocol that would allow researchers to simultaneously study different vaccines instead of studying each vaccine separately through independent studies by pharmaceutical companies. The administration plans to speed up distribution by scaling up manufacturing capabilities as the vaccines enter large human trials. The goal of project “Operation Warp Speed” is to have 300 million doses of vaccine available by January.
In a media interview, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and a key member of the White House Coronavirus Task Force, said that developing a vaccine to combat the coronavirus outbreak by January was “doable.” Dr. Fauci said that it was possible to ready hundreds of millions of doses of a coronavirus vaccine by January. However, meeting the January deadline will ultimately depend upon whether the results of trials prove that the vaccine works.
“We're going to start ramping up production with the companies involved and you do that at risk, in other words you don't wait until you get an answer before you start manufacturing, you at risk, proactively, start making it, assuming it's going to work,” said Dr. Fauci. “And if it does, then you can scale up and hopefully get to that timeline.”
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
Mass Manufactured Nanoparticles to Deliver Cancer Drugs Directly to Tumors
Polymer-coated nanoparticles loaded with therapeutic drugs hold significant potential for treating cancers, including ovarian cancer. These particles can be precisely directed to tumors, delivering their... Read more
World’s Smallest Pacemaker Fits Inside Syringe Tip
After heart surgery, many patients require temporary pacemakers either to regulate the heart rate while waiting for a permanent pacemaker or to support normal heart rhythm during recovery.... Read more
AI-Powered, Internet-Connected Medical Devices to Revolutionize Healthcare, Finds Study
A new study suggests that artificial intelligence (AI)-powered, internet-connected medical devices have the potential to transform healthcare by enabling earlier detection of diseases, real-time patient... Read moreSurgical Techniques
view channel
New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation
Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more
Minimally Invasive Valve Repair Reduces Hospitalizations in Severe Tricuspid Regurgitation Patients
The tricuspid valve is one of the four heart valves, responsible for regulating blood flow from the right atrium (the heart's upper-right chamber) to the right ventricle (the lower-right chamber).... Read morePatient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read morePoint of Care
view channel
Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour
Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read moreBusiness
view channel
Expanded Collaboration to Transform OR Technology Through AI and Automation
The expansion of an existing collaboration between three leading companies aims to develop artificial intelligence (AI)-driven solutions for smart operating rooms with sophisticated monitoring and automation.... Read more